An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children's Oncology Group clinical trials-Reference-Cited by-同舟云学术

An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children's Oncology Group clinical trials

Published:2022-02-07 Issue:4 Volume:69 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatric Blood & Cancer

Author:

Haduong Josephine H.¹^ORCID,Heske Christine M.²,Allen‐Rhoades Wendy³,Xue Wei⁴,Teot Lisa A.⁵,Rodeberg David A.⁶^ORCID,Donaldson Sarah S.⁷^ORCID,Weiss Aaron⁸,Hawkins Douglas S.⁹^ORCID,Venkatramani Rajkumar¹⁰

Affiliation:

1. Division of Oncology, Hyundai Cancer Institute Children's Hospital Orange County Orange California USA

2. Pediatric Oncology Branch, Center for Cancer Research National Cancer Institute Bethesda Maryland USA

3. Division of Pediatric Oncology Mayo Clinic Rochester Minnesota USA

4. Department of Biostatistics, College of Public Health and Health Professions and College of Medicine University of Florida Gainesville Florida USA

5. Department of Pathology Boston Children's Hospital/Harvard Medical School Boston Massachusetts USA

6. Division of Pediatric Surgery East Carolina University Greenville North Carolina USA

7. Department of Radiation Oncology Stanford University Stanford California USA

8. Division of Pediatric Hematology‐Oncology Maine Medical Center Portland Maine USA

9. Division of Hematology/Oncology, Seattle Children's Hospital University of Washington Seattle Washington USA

10. Department of Pediatrics, Texas Children's Hospital Baylor College of Medicine Houston Texas USA

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.29511

Reference74 articles.

1. Pediatric Rhabdomyosarcoma

2. Rhabdomyosarcoma

3. The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major Lessons From the IRS-I Through IRS-IV Studies as Background for the Current IRS-V Treatment Protocols

4. Pathology of childhood rhabdomyosarcoma: A consensus opinion document from the Children's Oncology Group, European Paediatric Soft Tissue Sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Contemporary preclinical mouse models for pediatric rhabdomyosarcoma: from bedside to bench to bedside;Frontiers in Oncology;2024-02-02

2. Adolescents and young adults with rhabdomyosarcoma: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group;Pediatric Blood & Cancer;2024-01-28

3. Histogram Analysis of Apparent Diffusion Coefficient Maps Provides Genotypic and Pretreatment Phenotypic Information in Pediatric and Young Adult Rhabdomyosarcoma;Academic Radiology;2024-01

4. TRIB3 silencing promotes the downregulation of Akt pathway and PAX3-FOXO1 in high-risk rhabdomyosarcoma;2023-12-03

5. Magnetic resonance imaging analysis of embryonal rhabdomyosarcoma of the prostate;Technology and Health Care;2023-11-16